EGFR and lung adenocarcinoma: In addition, Zhang et al. identified miR-608 and miR-4513 single nucleotide polymorphisms as independent candidate biomarkers for predicting survival in lung adenocarcinoma patients after EGFR-TKI treatment by systematically screening the database of 1000 genomic projects in miRbase and obtaining data from 319 stage IIIB/IV patients treated with EGFR-TKI [123].